The UK’s Answer to Darpa Wants to Reengineer the Human Brain

The best of the UK Research and Innovation Agency (ARIA) was it was launched in 2023 with the aim of aiming to shoot the moon “the most dangerous, the most profitable” in phases from the promotion food security to additional methods human security.

With more than $1 billion (about $1.3 billion) in public funding set between now and 2030, one of ARIA’s most ambitious programs is A total of £69 million which aims to develop similar ways to modify the human brain. The hope is to treat a variety of conditions, from epilepsy to Alzheimer’s.

Reports in the past have estimated that these nerve-wracking events will damage the UK economy many billions every year. According to ARIA program director Jacques Carolan, the common link is that they are all problems with the brain’s circuitry.

“Sometimes there are circuits that are over-connected, disconnected, there are different parts of the brain at play, there are different types of cells,” said Carolan, speaking at WIRED Health in London on April 16. “Our current results don’t have the precision that we need. The vision of this program is, ‘Can we create a more accurate neurotech model for neurotech?’

So far, ARIA’s track record for this month’s shoot has seen them pay 19 different teams. They are developing ideas ranging from using ultrasound as a new way to “biotype” a patient’s brain, to special brain stimulation techniques that can protect and repair different parts of the brain.

At WIRED Health, Carolan demonstrated the potential of ultrasound technology not only to change the brain, but also to allow scientists to discover new information about the brain’s circulation in a particular patient. One ARIA sponsored group at Imperial College London is to work combining ultrasound and gene therapy to measure gene expression in real time in neurons, which could allow scientists to determine in detail why certain brain networks are malfunctioning.

Over the past 25 yearsthe idea of ​​placing electrodes inside the brain and using them to stimulate a certain area, called the basal ganglia, has emerged as a new treatment for patients with advanced Parkinson’s disease. It has provided a new way to deal with motor symptoms when medical treatment is no longer working. In the future, says Carolan, similar techniques could be used for other debilitating neurological conditions, an idea he sees as the future of neurotherapeutics.

“What people have discovered is that the same technology can be used to treat things like depression, addiction, epilepsy, many chronic conditions,” he said. “It’s proof that we can have platform technologies that can handle different things.”

Given the lofty goals of ARIA, many question how it will assess whether its programs are succeeding or failing. But as Kathleen Fisher, CEO of ARIA, pointed out to WIRED Health, there can be a downside benefit to unanticipated research data.

Fisher, who previously worked at Darpa, the US Department of Defense agency that ARIA is based on, saw huge financial potential early on in the government. In 2013, Darpa awarded $25 million to support the development of vaccine platforms that can be manufactured very quickly.

“That company was Moderna,” Fisher recalled. “That technology was mRNA, a technology that came online just in time for Covid.” The subsequent release of the vaccine went on to save many lives from the Covid-19 pandemic.

Fisher’s goal is that by the early 2030s, ARIA will have already started to show “socially relevant seeds” either in its brain research or in another area that leads to the UK government re-funding the organisation.

“We may be starting to see trials that show we can do[brain]circuit manipulation in a way that doesn’t require surgery,” Fisher said. “Will we win in seven years?